Palisade Bio, Inc.(PALI)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Palisade Bio maintains a debt-free capital structure with $132.6 million in cash as of 2026Q1, providing a significant runway to advance its clinical pipeline despite the absence of recurring revenue.
• The company's reliance on external financing is evidenced by an accumulated deficit of $162.3 million, which necessitates successful clinical milestones to justify the current valuation.
• Investors should monitor the escalating R&D expenditure, which reached $6.4 million in 2026Q1, as the firm remains entirely dependent on its cash reserves to sustain operations.